title: Efficacy of topically delivered moxifloxacin against wound infection by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.
abstract: Wound infection is a common risk for patients with chronic nonhealing wounds, causing high morbidity and mortality. Currently, systemic antibiotic treatment is the therapy of choice, despite often leading to several side effects and the risk of an insufficient tissue penetration due to impaired blood supply. If systemically delivered, moxifloxacin penetrates well into inflammatory blister fluid, muscle, and subcutaneous adipose tissues and might therefore be a possible option for the topical treatment of skin and infected skin wounds. In this study, topical application of moxifloxacin was investigated in comparison to mupirocin, linezolid, and gentamicin using a porcine wound infection and a rat burn infection model. Both animal models were performed either by an inoculation with methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa. Wound fluid, tissue, and blood samples were taken, and bacterial counts as well as the moxifloxacin concentration were determined for a 14-day follow-up. A histological comparison of the rat burn wound tissues was performed. Both strains were susceptible to moxifloxacin and gentamicin, whereas mupirocin and linezolid were effective only against MRSA. All antibiotics showed efficient reduction of bacterial counts, and except with MRSA, infected burn wounds reached bacterial counts below 10(5) CFU/g tissue. Additionally, moxifloxacin was observed to promote wound healing as determined by histologic analysis, while no induction of bacterial resistance was observed during the treatment period. The use of topical antibiotics for the treatment of infected wounds confers many benefits. Moxifloxacin is therefore an ideal candidate, due to its broad antibacterial spectrum, its high efficiency, and its potential to promote wound healing.
authors.affiliation: Department of Plastic Surgery, Burn Center, BG University Hospital Bergmannsheil, Ruhr University Bochum, Buerkle-de-la Camp Platz 1, 44789 Bochum, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Jacobsen
authors.forename: C
authors.initials: C
authors.lastname: Fisahn
authors.forename: M
authors.initials: M
authors.lastname: Sorkin
authors.forename: I
authors.initials: I
authors.lastname: Thiele
authors.forename: T
authors.initials: T
authors.lastname: Hirsch
authors.forename: I
authors.initials: I
authors.lastname: Stricker
authors.forename: T
authors.initials: T
authors.lastname: Klaassen
authors.forename: A
authors.initials: A
authors.lastname: Roemer
authors.forename: B
authors.initials: B
authors.lastname: Fugmann
authors.forename: L
authors.initials: L
authors.lastname: Steinstraesser
mesh_terms: D000287:Administration, Topical; D000818:Animals; D001372:Aza Compounds / Q000008:administration & dosage* / Q000627:therapeutic use*; D024841:Fluoroquinolones; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000472:pathogenicity*; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000472:pathogenicity*; D011804:Quinolines / Q000008:administration & dosage* / Q000627:therapeutic use*; D051381:Rats; D013552:Swine; D014946:Wound Infection / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin